# Presentation: 696999

## Slide 1

## Budget Update

**Budget Update**

**Recent NIDA Activities**
** ****& Events**

**Policy Issues**

## Slide 3

## NIDA  BUDGET

**(Thousands)**

**Increase Over**** Prior Year**

**AIDS**

**TOTAL**

**NonAIDS**

## Slide 5

## NIH Resources to Aid Victims of

**NIH Resources to Aid Victims of**
** ****Hurricane Katrina**

**Medical Consultation Line for Patients**
**1-866-887-2842**

**Information for Displaced Clinical Trial **
**Participants**

**Information for the Biomedical Community**
**http://grants1.nih.gov/grants/katrina/index.htm**

## NIDA’s Response Thus Far Has Included...

**(+ 2 that Collaborate with Projects Affected)**

***NIDA’s Response Thus Far Has Included...***

**	****CTN Node Involvement**
**          ****Notice to Expand Immediate Response RFA **
**	****(released September 15, 2005)**
**	****Offered NIDA as a resource to SAMHSA’s Emergency **
**          ****Response Center (SERC) to complement & support **
**          ****their activities**
**          ****NIDA Personnel Deployment **
**	****    ****	**
**	****Conference Calls on  **
**                ****Relapse Prevention**
**                ****HIV/AIDS**

## Examples of       CTN Node Efforts 

**Examples of       CTN Node Efforts **

**Texas Node**** ****--**** ****Personnel helping **
**out at designated shelters at the **
**Reunion Arena and Convention Center in Dallas; **
**University of Texas SW Medical Center has been **
**in charge of the Mental Health facilities at these locations**
**Florida Node**** ****--**** ****Pledged to provide treatment to any relocated citizens in need**
**New Mexico Node**** ****--**** ****Volunteering at initial staging area in Albuquerque; **
**Providing substance abuse care as needed when victims pass through Santa Fe**
**Delaware Valley Node**** ****--**** ****Contributed to NAATP’s Hurricane Relief Fund**
**Northern New England Node**** ****--**** ****Deployed personnel to Louisiana to **
**provide emergency psychiatric/addiction psychiatric aid to victims**

## Mechanism for Time-Sensitive 

**Mechanism for Time-Sensitive **
**Research Opportunities (PAR-05-150)**
**(currently co-sponsored by NIDA and NIMH **
**and limited to Services Research)**

**Notice of Mechanism for Time-Sensitive Research **
**Opportunities: Expansion to Include Alcohol and Drug Abuse**
**Research Pertaining to Hurricane Katrina (NOT-DA-05-013)*****Issued September 15, 2005***

## Recent NIDA Activities

**Recent NIDA Activities**
**& Events**

## NIDA Council Workgroups

**NIDA Council Workgroups**

## Minority/Health Disparities

**Minority/Health Disparities**

## Minority/Health Disparities

**Minority/Health Disparities**
**Workgroup Recommendations**

**Interdisciplinary teams for research in health disparities**
**Reductions in health disparities should be a NIDA priority **
**Enhance organization and collaboration**
**Increase training for minority researchers**
**Incentives to promote valid analysis on minorities**
**Address research needs and priorities**

**Concerned about the limited research in**
**Native American populations**

## The Consequences of Drug Abuse and Addiction Disproportionately Affect Minority Populations

**The Consequences of Drug Abuse and Addiction Disproportionately Affect Minority Populations**

**0%**

**20%**

**40%**

**60%**

**80%**

**100%**

**70**

**11**

**12**

**6**

**Population **

**65**

**16**

**15**

**4**

**26**

**50**

**23**

**1**

**White**

**Black**

**Hispanic**

**Other**

**Incarcerated **
**for Drug**
**          ****Offense *** **

**23**

**58**

**1**

**19**

***Sources: * 2002 NSDUH, DHHS, SAMHSA, 2003. **  CDC  HIV/AIDS Surveillance Report 2002.***
******  Prisoners in 2002, BJS Bulletin, DOJ/OJP, July 2003.****** ******(estimated number of sentenced prisoners under State jurisdiction, 2001)******  ******	***

***Address Research Needs and Priorities***

## Opportunities in Health Disparities Research

**Among 8****th****, 10****th**** and 12****th**** graders, blacks**
**consistently have the lowest rate of illicit drug use**

**OPBRE**
**APR00**

**Source: *****Monitoring the Future Study, using two-year averages.***

**Percent Reporting Past Year Use of Any Illicit Drug**

**8****th**** Graders**

**10****th**** Graders**

**12****th**** Graders**

***Opportunities in Health Disparities Research***

## NonMedical Use of Stimulants in Persons 

**Lifetime Use**
**Past Month Use**

**Percent**

**NonMedical Use of Stimulants in Persons **
**Aged 12 & Older, **
**By Race/Ethnicity, 2003 **

***Source: SAMHSA, The NSDUH Report, Stimulant Use 2003, February 4, 2005.***

**White**

**Black or**
**African**
**American**

**Hispanic**
** ****or**
**Latino**

**Native **
**American/**
**Alaska**
**Native**

**Native **
**Hawaiian/**
**Pacific **
**Islander**

**Asian**

**10.7%**

**2.7%**

**5.0%**

**10.2%**

**8.3%**

**2.8%**

**0.6%**

**0.2%**

**0.4%**

**1.0%**

**0.2%**

## Interdisciplinary teams for research in health disparities

**     ****PA Interdisciplinary centers for drug abuse research**
**     ****RFA for training of interdisciplinary neuroscientists**
**     ****Identify new initiatives that have as a backbone**
**     ****interdisciplinary research:**
**    **
**2. *****Reductions in health disparities should be a NIDA priority***
**     ****Research on health disparities is a priority for NIDA**
** **

***RFA for social neurosciences***
***Initiative between DESPR and DBNBR to develop***
***methods for phenotypic characterization of the***
***environment***

## 3.  Enhance organization and collaboration

**    ****Improve the database to coordinate and monitor research that relates to health disparities**
**    ****NIDA Health Disparities Strategic Plan**
**         ****Input from NIDA Divisions and Centers**
**         ****Input from Working Groups**
**         ****Input from Council**
**    ****Minority Workgroups**
**         ****Reorganize workgroups**
**         ****Identify milestones  *****Training of minorities***
***                                                  ******Integrate research***
***                                                  ******Identify opportunities***
**         ****Annual evaluation of progress**

** **

##   3.  Enhance organization and collaboration

**      ****NIDA workgroup on health disparities with**
**      ****representative of each Division and Center**
**      ****with presentation to the NIDA Director on**
**      ****opportunities (prior to each Council meeting)**
**      ****Joint PA/RFA (i.e., HIV/AIDS & AA)**
**      ****Explicit mention of health disparities in all **
**      ****relevant RFAs and PAs from NIDA**
**      ****Yearly evaluation to assess progress**

** **

## Increase training for minority researchers

**     ****Supplement for training of minority researchers**
**     ****Use of minority working groups to identify trainees and mentors and evaluation of yearly progress in**
**     ****the training of minority researchers**
***Incentives to promote valid analysis on minorities***
**     ****Supplement grants when appropriate to enable the collection and analyses of samples in minority populations**
***6. Address research needs and priorities***
**     ****HIV/AIDS in AA**
**     ****Drugs and the criminal system in minorities**

## Basic Science Review Workgroup

** ****A background review of the current Basic Science program **
**    ****portfolio**
** ****Recommendations to fortify the current Basic Science program**
**   ****research mission**
** ****Input into the 5-year plan for NIDA’s Basic Science program**
**   ****with an emphasis on:**
**          ****epigenetics (interactions of environment and genetics)**
**          ****neurobiology of social behaviors**
**          **

***Charge:  To produce a written report that includes...***

***NIDA Council Members***

***Other Potential Members***

**Basic Science Review Workgroup**

**Linda Porrino, Chair**

**Barry Lester**

**Nancy Zahniser**

**F. Ivy Carroll**

**Yasmin Hurd **

**Gregory Gerhardt**

**Stanley Watson**

**Michael Nader**

**Marina Picciotto**

**Kathryn Cunningham**

## NIDA’s Approach to Grant-Making Work Group

***NIDA Council Members***

***Other Potential Members***

**Linda Porrino**

**Scott Lucas**

**Kathleen Carroll**

**Constance Weisner, Chair**

**David Vlahov**

**Claire Sterk**

**Mark Greenberg**

**Rudolfo Arredondo, Jr.**

**NIDA’s Approach to Grant-Making Work Group**

## PAs and RFAs Just Issued by NIDA

**     ****(PA-05-118) **
**Science Education Drug Abuse Partnership **
**    ****Award (PA-05-105) **
**Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders (RFA-DA-06-002)**

**PAs and RFAs Just Issued by NIDA**

**10 New PAs and 4 New RFAs**

**Foci include:**
**Neuroimaging**
**HIV/AIDS**
**Co-morbidity**
**Health Services**
**Research Training**

**...****With Other NIH Components/Agencies**

## Prescription Opioid Abuse and Pain 

***Notice of Intent to Publish***** an RFA titled:**
**Prescription Opioid Abuse and Pain **
**(NOT-DA-05-009)**

**Released July 8, 2005**

***Notice of Intent to Publish***** an RFA titled:**
**Social Neuroscience (NOT-DA-05-011)**
**(With NIAAA)**

**Released September 7, 2005**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**HIV/AIDS Research**

## NIH Priorities for AIDS-Related Research

**  ****Health Disparities**
**    **** **
**  ****Role of Non-Injection Drug Use In the Acquisition **
**    ****and Transmission of HIV**
**  ****International HIV/AIDS Research**
**  ****Training of Domestic and International HIV/AIDS**
**    ****Researchers**
**  ****Translation of HIV/AIDS Research Findings into**
**     ****Practice**

***In agreement with OAR Review ***

## NIH Priorities for AIDS-Related Research

**  ****Treatment Studies Among HIV-*****Un*****infected Individuals**

***Not In agreement with OAR Review ***

***Since drug abuse treatment has been shown to be ***
***associated with reductions in risk behavior and ***
***HIV incidence, funding HIV prevention studies ***
***using drug treatment modalities in high-risk populations***
***(Meth abusers, criminal justice populations) is important ***

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DPMCDA**

## Medications Development 

**Medications Development **
**Scientific Workgroup **

***Recommendations:***
*** ***

***Second Meeting***
**July 26-27, 2005**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**Special Population/**
**Health Disparities**

**Dr. Lula Beatty Will Report on **
**NIDA’s Recent Minority Health**
**Disparities Activities**

## Slide 31

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DBNBR**

## Comprehensive collection of nulls made publicly available is of 
    clear importance for understanding mammalian gene function
    and modeling human disease

NIH ICs are currently spending $34M to $83M (conservative 
    estimate) on production of mutants and initial phenotyping per year

Many of these mice do not make their way into repositories 
    for public distribution

**The NIH Knockout Mouse Project (KOMP)**

**Comprehensive collection of nulls made publicly available is of **
**    ****clear importance for understanding mammalian gene function**
**    ****and modeling human disease**
**NIH ICs are currently spending $34M to $83M (conservative **
**    ****estimate) on production of mutants and initial phenotyping per year**
**Many of these mice do not make their way into repositories **
**    ****for public distribution**

**Notes:**
Jane: introduce program by going over Banbury background, Slide 1, rationale for B’bery recommendations, Slide #2

## NIH KOMP Initiatives

**Released 2 RFAs (NHGRI):**
**Completion of a Comprehensive Mouse Knockout Resource (HG-05-007) -- *****up to $10 M per year for 5 years***
**A Data Coordination Center for the Knockout Mouse Project (HG-05-008) -- *****$500 K per year for 5 years***
**Released RFA (NIDA)**
**Development and Improvement of Inbred ES Cell Lines for Use in Generation of Mouse Mutants (DA-06-009) -- *****up to $1.6 M per year for 3 years***
**Currently developing 4****th**** RFA for the Repository and Repatriation component**
**18 NIH Institutes participating**** in the KOMP**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DESPR**

## DESPR New Initiatives

**    ****studies funded by NIDA, NIAAA and NIMH**
** ****Evaluate the CJ-DATS for a clinical trial on**
**     ****naltrexone depot for the treatment of opiate addicts**
** ****Help develop scientific infrastructure to enable other**
**    ****countries to analyze epidemiological data on patterns**
**    ****of drug abuse and its impact on HIV**
** ****Collaboration with DBNBR to genotype**
**    ****methamphetamine abusers to ensure adequate **
**    ****sampling in minority populations**
** ****Community Based Treatment and Prevention RFA**

**DESPR New Initiatives**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DCNDBT**

## Behavioral Treatment 

- Copyright ©2003 by the National Academy of Sciences

***Source: Temple, Elise et al. (2003)***
*** ******Proc. Natl. Acad. Sci. USA 100, 2860-2865***

**Behavioral Treatment **
**Can Affect Brain**
**Structure and Function **

## Neurobiology of Behavioral Treatment: 

**Neurobiology of Behavioral Treatment: **
**Recovery of Brain Structure and Function**
**RFA-DA-05-006**

***22 Applications Received***
***Reviewed July 12, 2005***
***Council Review – September 2005***

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience, **
**Development &**
**Behavioral**
**Treatment**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**CCTN**

## New Nodes Awarded 

***September 1, 2005:***
**Texas Node**
**Appalachian Tri-State Node**
***Node Name Changes:***
**Oregon Node *****to****** *****Oregon/Hawaii Node**
**South Carolina Node *****to****** *****Southern Consortium**

**Notes:**
Modified 1/11/01 – 14 Sites

## Update on New CTN Protocols

**     ****and methadone on liver function *****10 sites, Spring 2006***
**2.  Prescription Opioid Addiction Treatment Study (POATS)**
**     *****~ 12 sites, Spring 2006***
**3.  Randomized Controlled Trial of Methylphenidate in Adolescents with ADHD and Substance Use Disorders**
**     *****10 sites,***** *****Fall 2005***
**4.  Methylphenidate in Maintaining Abstinence in Smokers**
**     ****with ADHD  *****6 sites, Fall 2005***
**Developing protocol to assess the utility of 12-Step **
**     ****Facilitation in increasing 12-Step participation and **
**     ****improving drug abuse treatment outcomes (in cocaine **
**     ****and meth abusers)**

**Update on New CTN Protocols**

## Slide 43

## PIONEER AWARD 

**The NIH Director’s**
**PIONEER AWARD**** **

***A component of the NIH Roadmap for Medical Research***
**...****supports scientists of exceptional creativity **
**who take innovative approaches**
**to major challenges in biomedical research**

**9 Awards were made in 2004...**
**   ****These investigators will present at... **

**5-10 2005 Awards**
**will be announced**

##   Integration of Clinical Research Networks

**  ****Integration of Clinical Research Networks**
**  ****Clinical Research Training and Career Development**
**  ****Enabling Technologies for Improved Assessment of**
**    ****Clinical Outcomes**
**  ****Harmonization of Clinical Research Policy**
**  ****Institutional Clinical and Translation Science Awards**
**  ****Interdisciplinary Research (within the Roadmap**
**    ****theme: *****Research Teams of the Future*****)**

## Molecular Libraries Meeting    

**  ****Orientation and Background of MLSCN**

**  ****Presentations by NIDA-supported investigators on cellular**
**    ****signaling, receptor trafficking and molecular structure**
**    ****important in addiction**** **

**  ****Presentations by experts in basic assay development **

**  ****Presentations of assays and screening targets of interest **
**    ****to NIDA**** **

**  ****Discussion and Recommendations for NIDA**** **

**Molecular Libraries Meeting    **
**October 18 and 19, 2005**
**        ****To explore the opportunities offered by**
**        ****the NIH Molecular Libraries Screening **
**        ****Centers Roadmap Initiative **
***       ******The agenda will include the following topics:***

## Recent and Upcoming Meetings,

**Recent and Upcoming Meetings,**
**Conferences and Events**

## Congressional Briefings, Hearings & Events

**NIH Research in Action:Innovative**
**Behavioral Treatments for Mental & **
**Substance Abuse Disorders**
**May 4, 2005 -- *****Sponsored by the American ***
***Psychological Association’s Science Policy Office***
**Methamphetamine Addiction: **
**Cause for Concern – Hope for the Future**
**June 28, 2005 -- *****Sponsored by the ******Friends of NIDA******,***
***the Congressional Methamphetamine ***
***Caucus & the Congressional Addiction ***
***Treatment & Recovery Caucus***

**Congressional Briefings, Hearings & Events**

**PRISM Premiere on Capitol Hill**
**September 13, 2005**** **

***Entertainment Industries Council (EIC) ***
***is editing a piece that will air multiple ***
***showings later this year***

**9****th**** Annual **
**PRISM Awards Event  **
**Beverly Hills Hotel**
**April 28, 2005**

## Mentored K Awardees Meeting: 

**Mentored K Awardees Meeting: **
***Making the Transition ***
***to Independent Scientist***
**August 3-4, 2005**

## Slide 50

## Slide 51

** **
** **
** **
** **
**Addiction and Obesity – Brain Systems Commonalities**
**Presentation by the Jacob A. Waletzky Award Recipient**
**Neurobiological Basis for Co-occurring Substance Abuse**
**  ****& Mental Illness**
**Poster Session:  Early Career Investigators**
**mGluR: A Substrate in the Neurobiology of Addiction**
**Reconsolidation of Memory: A New Approach to Treat **
**   ****Drug Addiction? **
**Adolescent Drug Abuse:  Brain Development, Cognition **
**   ****& Vulnerability**
** **
** **
** **

***November 11, 2005 -- 8:00AM to 9:00PM***

## Slide 53